We first examined the effect of the Q165P mutation on BRD2, BRD3, and BRD4 protein levels in the Q165P heterozygously mutated primary PCa biopsy using immunohistochemistry (IHC) (Figs 1D and EV1C). The gene discussed is BRD2; the disease is posterior cortical atrophy.